TB-500 Guide

TB-500 is commonly used online to refer to a synthetic thymosin beta-4 fragment. FDA substance records list TB-500 as the N-terminal acetylated 17-23 fragment of thymosin beta-4, and anti-doping literature has identified the fragment as Ac-LKKTETQ. [1][4]

That distinction matters. Full-length thymosin beta-4 is a naturally occurring 43-amino-acid protein studied in wound, ocular-surface, and tissue-repair models. TB-500, as commonly described in the research-chemical market, is a smaller fragment. Evidence from full-length thymosin beta-4 should not be automatically treated as evidence for consumer TB-500 products. [4][5][7][8]

This page is educational. It does not provide dosing, reconstitution instructions, sourcing guidance, or treatment advice. Readers should treat marketed TB-500 claims with caution, especially claims about injury recovery, muscle repair, or systemic healing in humans. [2][3]

Thymosin beta-4 biology is usually discussed through actin regulation, cell migration, angiogenesis, and inflammatory signaling. The actin cytoskeleton helps cells move and remodel tissue during repair processes, which is why thymosin beta-4 has attracted interest in wound-healing and ocular-surface research. [5][7]

The LKKTETQ region is often described as an important actin-binding motif. In a 2003 FASEB Journal study, thymosin beta-4 and a seven-amino-acid actin-binding motif promoted endothelial-cell migration and vessel-sprouting assays in experimental systems. Those findings help explain the repair hypothesis, but they are not proof that unapproved TB-500 products improve human injury recovery. [5]

Mechanism claims should also be interpreted in both directions. A pathway that encourages cell migration or angiogenesis can be relevant to repair, but it also raises questions about context, dose, route, tissue state, and long-term risk. The biology is not a simple synonym for safety or benefit. [2][5]

Human evidence is stronger for investigational thymosin beta-4 formulations than for the TB-500 fragment itself. Published human work includes topical or ophthalmic thymosin beta-4 studies, such as venous ulcer research and RGN-259 ophthalmic trials for dry eye or neurotrophic keratopathy. [6][7][8]

A 2007 Annals of the New York Academy of Sciences paper described a double-blind, placebo-controlled, dose-escalation study design for topical thymosin beta-4 in venous ulcers, focused on safety, tolerability, and healing endpoints. This was not a consumer injectable TB-500 protocol. [6]

A 2015 Phase 2 dry-eye study tested 0.1% thymosin beta-4 ophthalmic solution in 72 subjects. The primary endpoints did not both separate from placebo, but several secondary endpoints improved and no adverse events were reported in that study. [7]

A later Phase 3 neurotrophic keratopathy study of 0.1% RGN-259 reported a healing trend and additional comfort findings in a small trial population. This is ocular-surface research with a formulated sterile eye-drop product, not evidence that online TB-500 vials are safe or effective for systemic recovery. [8]

Claims about faster wound healing and tissue repair are biologically plausible because thymosin beta-4 research includes cell-migration, angiogenesis, anti-inflammatory, dermal-wound, and ocular-surface findings. The most defensible wording is that the pathway is being studied, not that TB-500 is proven to heal injuries in routine human use. [5][6][7][8]

Claims about tendon repair, muscle tears, joint recovery, flexibility, or athletic performance are much less settled. Those claims are common in commercial and fitness discussions, but this profile did not identify high-quality human trials showing that TB-500 fragment products improve those outcomes. [2][3][4]

Claims about anti-inflammatory effects should also be kept narrow. Inflammation is part of normal repair, immune defense, and disease biology. A peptide that changes inflammatory or tissue-remodeling pathways may have different effects depending on route, sterility, impurities, medical history, and the tissue being targeted. [2][5]

FDA materials specifically flag safety-information gaps for thymosin beta-4 fragment LKKTETQ, also known as TB-500. FDA states that compounded products containing the fragment may pose immunogenicity risks for certain routes because of potential aggregation and peptide-related impurities, and that FDA has not identified human exposure data for drug products containing the fragment. [2]

The same FDA page says the agency lacks important information about whether the drug would cause harm if administered to humans. That is a stronger caution than simply saying more research is needed: it means public safety conclusions cannot be inferred from marketing claims or from unrelated thymosin beta-4 studies. [2]

For athletes and tested competitors, WADA lists thymosin-beta-4 and derivatives such as TB-500 under prohibited growth-factor related substances. This matters even if a product is labeled as research-only, because anti-doping rules focus on substance status and athlete responsibility. [3]

Published ocular studies of formulated thymosin beta-4 products reported favorable short-term tolerability in their specific trial contexts, but those data do not validate unapproved peptide vials, non-sterile handling, different routes, different concentrations, or long-term unsupervised use. [7][8]

There is no public FDA-approved TB-500 product label that can be used as a reliable consumer storage standard. FDA substance identifiers also do not imply regulatory approval, and seller-provided storage instructions should not be treated as evidence that a product is legitimate, sterile, or suitable for human use. [1][2]

This profile intentionally does not provide reconstitution, injection, storage-duration, or transport instructions. For peptides intended for human drug use, handling conditions should come from validated manufacturing controls, official labeling, or an authorized clinical-trial protocol, not from forums or vendor pages. [1][2]